A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.

被引：29
作者：
Finn, Richard S.
Javle, Milind M.
Tan, Benjamin R.
Weekes, Colin D.
Bendell, Johanna C.
Patnaik, Amita
Khan, Gazala Naaz
Laheru, Dan
Anderson, Lisa
Christy-Bittel, Janna Lynn
Barrett, Emma
Guthrie, Kari
Litwiler, Kevin S.
Bekaii-Saab, Tanios S.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Washington Univ, Sch Med, St Louis, MO 63110 USA
[4] Univ Colorado, Canc Ctr, Aurora, CO USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] South Texas Accelerated Res Therapeut START, Ctr Canc Care, San Antonio, TX USA
[7] Univ Michigan Hosp, Ann Arbor, MI USA
[8] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[9] Array BioPharma, Boulder, CO USA
[10] Ohio State Univ, Med Ctr, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
220
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase Ib dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Grisham, Rachel N.
    Gordon, Michael S.
    Harb, Wael A.
    Aghajanian, Carol
    McMeekin, D. Scott
    McKinley, Kristin
    Anderson, Lisa Renee
    Chavira, Renae
    Christy-Bittel, Janna
    Barrett, Emma
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Phase Ib and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid malignancies
    Adjeil, A.
    Cohen, R. B.
    Franklin, W. A.
    Molina, J.
    Hariharan, S.
    Temmer, E.
    Brown, S.
    Maloney, L.
    Morris, C.
    Eckhardt, S. G.
    EJC SUPPLEMENTS, 2006, 4 (12): : 12 - 12
  • [33] Synergism analysis of dose matrices for combinations of BKM120 (a PI3K inhibitor), MEK162 (a MEK1/2 inhibitor) and chemotherapy in colorectal cancer (CRC) cell lines
    Tosi, Diego
    Atis, Salima
    Mollevi, Caroline
    Martineau, Pierre
    Gongora, Celine
    CANCER RESEARCH, 2014, 74 (19)
  • [34] Synergism analysis of dose matrices for combinations of BKM120 (a PI3K inhibitor), MEK162 (a MEK1/2 inhibitor) and chemotherapy in colorectal cancer (CRC) cell lines
    Tosi, Diego
    Atis, Salima
    Mollevi, Caroline
    Vie, Nadia
    Martineau, Pierre
    Gongora, Celine
    CLINICAL CANCER RESEARCH, 2015, 21
  • [35] A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS-RAF PATHWAY-ACTIVATED TUMORS: INITIAL REPORT
    Robison, Nathan
    Pauly, Jasmine
    Malvar, Jemily
    Filbin, Mariella
    de Mola, Rebecca Loret
    Dorris, Kathleen
    Bendel, Anne
    Bowers, Daniel
    Bornhorst, Miriam
    Gauvain, Karen
    Leary, Sarah
    MacDonald, Tobey
    Gardner, Sharon
    Reddy, Alyssa
    Diaz, Patricia
    Tan, Yi Juin
    Sinai, Claire
    Davidson, Tom
    Ullrich, Nicole
    Margol, Ashley
    Dhall, Girish
    Borchert, Mark
    Ligon, Keith
    Sposto, Richard
    Kieran, Mark
    NEURO-ONCOLOGY, 2017, 19 : 189 - 189
  • [36] Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer
    Van Cutsem, Eric
    Yaeger, Rona
    Delord, Jean-Pierre
    Tabernero, Josep
    Siu, Lillian L.
    Ducreux, Michel
    Siena, Salvatore
    Elez, Elena
    Kasper, Stefan
    Zander, Thomas
    Steeghs, Neeltje
    Murphy, Danielle
    Edwards, Michelle
    Wainberg, Zev A.
    ONCOLOGIST, 2023, : e1209 - e1218
  • [37] Preclinical study of MEK1/2 inhibitor AZD6244 combined with gemcitabine for treatment of biliary cancer.
    Xu, Junyao
    Knox, Jennifer J.
    Tsao, Ming Sound
    Chen, Eric Xueyu
    Cao, Pinjiang
    Sue, Chow
    Serra, Stefano
    Hedley, David W.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [38] The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma
    Dummer, R.
    Flaherty, K.
    Kefford, R.
    Ascierto, P. A.
    Moutouh-de Parseval, L.
    Wasserman, E.
    Schadendorf, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (03) : E80 - E80
  • [39] ARRY-162: A novel MEK inhibitor: Results of a 14-day phase LA study in healthy subjects and a 28-day phase 1B study in rheumatoid arthritis patients
    Carter, Laura
    Brown, Suzy
    Klopfenstein, Nathalie
    Simmons, Heidi
    Litwiler, Kevin
    Nugent, Courtney
    Gaddis, Vicki
    Venendaal, Cynthia
    Kivitz, Alan
    Fogarty, Charles
    Yates, John
    Rojas-Caro, Sandra E.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S299 - S299
  • [40] Phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer.
    Lorusso, P
    Krishnamurthi, S
    Rinehart, JR
    Nabell, L
    Croghan, G
    Varterasian, M
    Sadis, SS
    Menon, SS
    Leopold, J
    Meyer, MB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 194S - 194S
12345